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Abstract
Evaluation of health-related quality of life (QoL) in people with pituitary tumours has received much attention over the last 10–15 years. Most of them 
show impaired QoL, but little is known about how to prevent impairment or how to improve QoL. Our aim is to review what is known about QoL in 
pituitary tumours patients and to highlight the areas worth improving, for the patient’s well being. The article has four sections: acromegaly, Cushing’s 
syndrome, prolactinomas and non-functioning adenomas. Control of comorbidities is usually an important factor to prevent QoL impairment; 
however, each disease has specific characteristics that should be properly addressed in order to obtain full patient recovery after successful therapy.
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Pituitary tumours are associated with pituitary dysfunction, either 
hypersecretion (mainly prolactinomas, acromegaly or Cushing’s disease 
[CD]) or hypopituitarism, due to compression or destruction of normal 
pituitary cells. They may also cause headache or visual disturbances 
due to pressure on surrounding structures.
Health-related quality of life (QoL) is a concept that refers to individual 
wellbeing. It is based on how a particular individual feels, responds and 
functions in daily life. Subjects will value their QoL, taking into account their 
expectations, standards and goals, as well as the emotional, physical and 
social aspects of their lives, which may be affected if a disease is present.1
There are two kinds of tools normally used to measure QoL: generic and 
specific questionnaires. In both, patients answer questions related to their 
perception of their health status. Answers can be rated in yes/no questions, 
a Likert scale (i.e. always, often, sometimes, rarely, never) or in a range (i.e. 
0–100). Generic questionnaires are useful in different populations, including 
healthy subjects. They can help to compare QoL in different diseases, for 
instance. Examples of generic questionnaires used in pituitary tumours are 
the Nottingham Health Profile (NHP),2 Short-Form 36 (SF-36),3 the EuroQoL4–6 
or the Psychological General Wellbeing Scale (PGWBS)7 (see Table 1). 
However, they are often not sensitive enough to appreciate particular 
problems that may be related to a certain disease. That is why disease-
specific questionnaires have been developed, more sensitive to 
detect subtle changes in QoL in a determined disease (for instance, 
improvement after treatment). For pituitary adenomas, questionnaires 
often used are AcroQoL for acromegaly,8 CushingQoL for Cushing’s 
syndrome (CS)9,10 and Adult Growth Hormone Deficiency Assessment 
(AGHDA)11 or Questions on Life Satisfaction-Hypopituitarism (QLS-H) for 
growth hormone (GH) deficiency12,13 (see Table 1).
The following section reviews what is known about QoL in patients with 
pituitary tumours, both at diagnosis and after treatment, highlighting 
what may be helpful to improve QoL.
Acromegaly
Acromegaly is a syndrome caused by chronic exposure to elevated 
levels of GH and peripheral insulin-like growth factor 1 (IGF-I). It is 
associated with morphological changes (including soft tissue swelling, 
excessive sweating and change in patients’ voice), often not completely 
reversible, with physical and psychological limitations (including joint 
pains, headache, low energy and libido). Due to the insidious nature of 
the disease, the diagnosis of acromegaly is significantly delayed, being 
undiagnosed for years, despite the presence of signs and symptoms, 
thus, the impact of the disease and its treatment on the patients’ QoL 
can be great.14–18
When compared with the general population, SF-36 questionnaire 
scores are lower in acromegaly, reflecting impairment of perceived QoL 
in physical function dimensions, but not in the mental ones.19 Successful 
surgery or medical treatment may be followed by marked improvement 
in the patient’s overall health, often, but not always, accompanied by 
improvement or normalisation of biochemical parameters such as GH 
and IGF-I. Since comorbidities occur after many years of exposure to 
excessive GH, an earlier diagnosis would benefit patients’ perceived 
health and QoL.20,21 The availability of a questionnaire, specifically designed 
to evaluate the problems typical of acromegaly (AcroQoL), has favoured 
research in this area. This is particularly important in consideration of the 
fact that GH and IGF-I do not always correlate with subjective and clinical 
improvements experienced by patients and physicians after treatment.22
With AcroQoL, lower scores in active disease have persistently 
been observed in different countries, compared with patients in 
remission after successful therapy, with appearance being the 
most affected dimension and the personal relations area the least 
affected.23–26 However, impairments in QoL, as assessed by the generic 
questionnaire PGWBS, persist in ‘cured’ acromegaly compared with the 
normal population and patients treated for a non-functioning pituitary 
adenoma, mainly in the domains of general health and vitality, and 
similarly bad or worse than adults with GH deficiency.27 
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Table 1: Generic and Disease-specific Questionnaires to Assess Health-related Quality of Life
Name and Interpretation Characteristics Reference
Generic questionnaires Nottingham Health Profile (NHP)
Higher: Worse QoL
It has six subscales: energy level, pain, 
emotional reaction, sleep, social isolation 
and physical abilities. Furthermore, it 
gives information on affected life areas 
(work, looking after home, social life, home 
life, sex life, interest and hobbies and 
vacations)
2
Short-Form 36 (SF-36)
Higher: Better QoL
It has 8 scales divided into physical health 
(physical functioning, role-physical, bodily 
pain and general health) and mental health 
(vitality, social functioning, role-emotional 
and mental health)
3
EuroQoL
VAS – Higher: Better QoL
5D – Higher: Worse QoL
It has a VAS to assess general wellbeing 
(similar to a thermometer) and 5D: mobility, 
self-care, usual activities, pain/discomfort 
and anxiety/depression
4–6
Psychological General Wellbeing 
Scale (PGWBS)
Higher: Better QoL
It has six subscales: anxiety, depressed 
mood, positive wellbeing, self-control, 
general health and vitality
7
Specific questionnaires Acromegaly AcroQoL
Higher: Better QoL
It includes 22 questions, can be scored 
globally or in two scales (physical and 
psychological). The psychological scale 
is subdivided into two further subscales: 
appearance and personal relations
8
Growth-hormone 
deficiency
AGHDA
Higher: Worse QoL
It is unidimensional, with 24 questions with 
Yes/No possibility
11
Questions on Life Satisfaction-
Hypopituitarism (QLS-H)
Higher: Better QoL
It is unidimensional with parts: the  
first presents the degree of agreement 
with the items; the second, the importance 
given by the individual to of each of  
the items
12,13
Cushing’s syndrome Cushing QoL
Higher: Better QoL
It is unidimensional, with 12 questions
9,10
Pharmacological treatment (either monotherapy or combination therapy) 
lower GH and IGF-1, and improve both acromegaly comorbidities and 
QoL.22,24,28–32 A double-blind study in acromegalic patients controlled on 
somatostatin analogue therapy showed how the addition of pegvisomant 
improved the AcroQoL score, without changes in IGF-1 levels.22 This 
highlighted the importance of including patient-reported outcome 
measures such as QoL assessment in clinical practice,22 since evaluation 
of perceived QoL and clinical improvement with these questionnaires 
could be more sensitive than IGF-I measurement. The AcroQoL results 
have questioned the current recommendations on assessment of 
disease activity in acromegaly with GH and IGF-I and highlighted the 
importance of including QoL assessment in daily practice. The chronic 
need of monthly injections of somatostatin analogues to control the 
disease has also been shown to impair AcroQoL scores.33 Patients treated 
with radiotherapy had low QoL scores, although it is unknown whether 
this relates to the more aggressive nature of the disease, which remains 
active after surgery and medical therapy.14,34,35 Disease duration, active 
disease, older age, female gender and presence of joint pain are also 
negatively correlated with the AcroQoL scores.14,34,36 Multidisciplinary 
teams with specific experience in pituitary disease, including experienced 
5D = five dimensions; AGHDA = Adult Growth Hormone Deficiency Assessment; QoL = quality of life; VAS = visual analogue scale.
dedicated pituitary neurosurgeons have higher success rates37–41 in long-
term outcome and this may improve QoL. The possibility to personalise 
therapeutic options on patients’ individual clinical and biochemical 
characteristics would determine better long-term prognosis and have a 
positive impact on patients QoL. Nevertheless, it is important to be aware 
of the persistent adverse effects of pituitary disease on QoL. Discussions 
with the patient could prevent inappropriate expectations in terms of the 
long-term results of treatment.
Among the factors affecting QoL, psychological status seems to be one 
of the most relevant. Acromegaly is associated with higher anxiety-
related traits and reduced novelty-seeking behaviour and impulsivity, 
compared with non-functioning adenomas, which may affect QoL, 
treatment adherence and patient–doctor contact.42 Patients described 
themselves as more harm avoidant and neurotic and showed a high 
social conformity. All these psychological aspects may be benefited by 
a proper treatment, which may also improve QoL.
When QoL is compared in different pituitary tumours using Z-scores 
(or standard deviation scores) for different generic questionnaires, 
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differences in age and gender (two determinants of QoL) are accounted 
for, and comparisons with reference populations are possible.43 Total QoL 
score and all subscales of the questionnaires are worse in acromegaly 
compared with controls, demonstrating impairment of QoL during 
long-term follow-up after treatment. More impairment for physical 
ability and functioning and more bodily pain were seen than in patients 
treated for non-functioning pituitary adenomas (NFA) or prolactinomas. 
Hypopituitarism further impaired multiple aspects of QoL.
Development of GH deficiency after treatment for acromegaly also 
affects QoL negatively. In fact, the patients least affected were those who 
attained a normal GH after treatment (i.e. between 0.3–1 mcg/l), while if 
GH was higher (reflecting active disease), or lower (indicating that these 
patients had become GH deficient),44 more impairment ensued. With the 
AGHDA score, young adult patients who became GH deficient due to prior 
treatment of acromegaly (with surgery and/or radiotherapy) improved 
their QoL after substitution therapy with recombinant human GH (rhGH).45 
However, this was not found in older patients with a mean age of 56 years.46
In summary, the availability of a disease-specific questionnaire as 
AcroQoL has confirmed that QoL is impaired in acromegaly, especially 
in active disease, if medical therapy is provided (with greatest impact on 
the appearance dimension), and if musculoskeletal symptoms (mainly 
pain) are present. Patients with acromegaly experience maladaptative 
personality traits, which may impact QoL. The physical dimensions 
of the AcroQoL questionnaire have been shown to be more sensitive 
than circulating IGF-I to detect patient’s improvement after adding 
pegvisomant to somatostatin analogue treatment in ‘controlled’ 
patients. In conclusion, an earlier diagnosis in order to prevent long-term 
complications, good disease control, specific approach to comorbidities 
and patient education on the disease and its consequences tend to 
be helpful to improve QoL in acromegaly. However, awareness of the 
incomplete reversibility of some QoL dimensions is important to prevent 
unrealistic expectations of the outcome of therapy.
Cushing’s Syndrome
The clinical features associated with hypercortisolism in patients with CS 
seem to be a strong determinant for wellbeing and QoL. QoL questionnaires 
used together with specific evaluations of cognitive functioning or 
depression have shown impaired QoL in CS.19,47–50 Several investigators 
have demonstrated greater impairment of QoL in active CS patients than in 
‘cured’ patients.10,47,48 However, cured CS patients failed to normalise their 
QoL, even long term after control of hypercortisolism.48,50,51 The degree 
of initial hypercortisolism is not associated with subsequent level of 
decreased QoL. Complex pharmacological treatments, need for frequent 
medical check-ups and concerns about future health deterioration due 
to comorbidity, also negatively affect QoL.51,52 Therefore, CS patients show 
more emotional problems (depression and anxiety) and slower recovery 
after surgery than other patients with pituitary adenomas.19,53 
Patients with CS most often complain of fatigue/weakness (85 %), changes 
in physical appearance (63  %), emotional instability (61  %), cognitive 
problems (49 %), depression (32 %) and sleeping difficulties (12 %).54 These 
problems in CS patients cause negative effects on family life, partner 
relations and work/school performance.54 Furthermore, a retrospective 
report showed low scores in questions regarding employment status and 
work capacity in CS patients both before and after treatment.55 Although 
after treatment, 81  % of CS patients were working, 11  % were retired 
because of disability, 5 % were retired because of age and 3 % were on 
sick-leave at the time of answering the questionnaire.55
The mechanism through which CS determines impairment of QoL is 
probably multifactorial, involving physical, medical and psychological 
factors. Impaired QoL has not been found to correlate with modality of 
treatment (pituitary or adrenal surgery or pituitary irradiation), duration 
of follow-up after biochemical remission, disease duration or severity 
of hypercortisolism.9,49,51 An European-wide study demonstrated 
that depression was the only negative predictor of QoL score (using 
the disease-specific CushingQoL questionnaire), whereas other 
variables such as delay to diagnosis, diabetes or hypertension did 
not significantly influence it.56 Most CS patients have depression or 
emotional lability especially if they are older, female and have severe 
hypercortisolism.57,58 Psychopathology (mainly atypical depression) 
was more prevalent before cure (66.7 %) than at three months (53.6 %), 
six months (36 %) and 12 months (24.1 %) after successful treatment.59
Some studies using generic questionnaires (NHP, SF-36, Multidimensional 
Fatigue Inventory-20 [MFI-20], Hospital Anxiety and Depression Inventory 
[HADS]) showed that pituitary radiotherapy led to greater QoL impairment 
in CS patients compared with those who had not been irradiated,51 but 
this observation was not confirmed with the CushingQoL questionnaire 
(a disease-specific questionnaire for measuring QoL in CS patients).9,10 
Wagenmakers et al.50 showed that hormonal deficiencies in patients in 
long-term remission of CS was associated with impaired QoL. Others 
have not found differences in the CushingQoL score in relation to the 
presence or not of hypopituitarism, although they described that longer 
duration of adrenal insufficiency did affect QoL negatively.9,10 Therefore, 
assessment of adrenal insufficiency is important in monitoring of 
patients, and to start on effective replacement as early as possible is 
fundamental for QoL of CS patients.
Studies seem to agree that there are no differences in QoL between 
patients with CS of pituitary or adrenal origin,9,10,50,56,60 suggesting that 
persistent QoL deficits after biochemical cure of CD are driven by the 
disease process and hypercortisolism itself, and not by the origin or 
eventual mode of curative therapy. QoL evaluation after uni- or bilateral 
adrenalectomy for CS has shown symptomatic improvement in all 
patients regardless of their primary diagnosis (adrenal adenoma, ectopic 
adrenocorticotropic hormone [ACTH], macronodular hyperplasia, CD, 
adrenocortical cancer and pigmented micronodular hyperplasia) and 
independently of the surgical procedure performed (laparoscopic or 
open bilateral adrenalectomy), similar to that found in patients treated 
with pituitary surgery or radiotherapy.61,62 When CD patients were asked 
to value the effect of adrenalectomy on QoL, 78 % (28/36) answered 
they had improved and 68 % (19/28) claimed a dramatic improvement, 
but 14  % (5/36) experienced no change and 8  % (3/36) stated that 
their QoL had worsened.63 Limited data comparing pre- and post-
treatment QoL in CD patients are currently available. Vitality/Fatigue 
and General Health in the treated group scored better than in the 
active, pre-treatment group, but to a lower degree than seen for the 
other scales.64 Fatigue was still present in 46 % of treated CD patients. 
However, the majority of these patients (86  %) felt that their health 
status was good to excellent, compared with one year before surgery, 
and 68 % reported no problems with moderate activities.64 Moreover, 
another report demonstrated that in CS patients, improvement of 
health-status perception is detectable a few months after surgery 
(4 ± 1.5 months), using the CushingQoL questionnaire.10 These data indicate 
that significant improvement of QoL is time dependent after therapy. 
In conclusion, despite successful treatment of CS, long-term residual 
effects on QoL persist. Handling physicians should advise patients that 
Improving Quality of Life in Patients with Pituitary Tumours
EUROPEAN ENDOCRINOLOGY 35
QoL recovery is progressive and slower than biochemical correction, 
independently of the cause of CS (adrenal or pituitary) and the modality 
of treatment. Patients should be warned that complete reversal of 
physical and psychological comorbidities does not occur immediately 
after surgery and poor wellbeing may be associated with persistent 
depression. Thus, appropriate treatment to reduce depressive 
symptoms is necessary to improve QoL in CS patients.
Non-functioning Pituitary Adenomas
Few and conflicting data on QoL on NFA have been published. 
Some studies demonstrated that QoL was reduced in treated NFA 
patients,19,43,65 in contrast with others showing that successful treatment 
led to normalisation of QoL compared with healthy population.66–68 
NFA are usually macroadenomas causing visual field defects and 
hypopituitarism. Visual field deficiencies were associated with reduced 
interest in leisure activities,66 without affecting the global QoL score.65,66 
However, post-operative hypopituitarism is a strong predictor of reduced 
QoL.43,65 In particular, NFA patients with hypogonadism showed worse 
social life and reduced daily activity in comparison to those having normal 
gonadotropin function or on correct hormone replacement.65,66 On the 
other hand, several studies have found that QoL is impaired in patients 
suffering GH deficiency,69–72 and impairment is worse if other pituitary 
deficits are present.73 NFA patients with GH deficiency showed impaired 
body pain, mental health and general health perception compared with 
GH-deficient patients,66 which improved after correct replacement with 
GH.74 Once treated, improvements can be found in QoL, cardiac function, 
body composition and lipid profile.13,75–79 Furthermore, patients also 
have improvements in sexual arousal and body shape after treatment, 
and have a very prompt improvement in dimensions of socialising and 
tenseness.80,81 This information gives more support to the idea that 
patients could benefit from GH-substitution therapy.
Altered sleep characteristics have been described in 17 patients after 
surgical removal of NFA.82 Disturbed sleep was associated with fatigue 
during the day and poor QoL.82 Reduced energy, fatigue (mental and 
physical), physical problems, lower activity and motivation were previously 
reported in another study on operated NFA patients.65 Thus, regulating 
patient’s sleep–wake cycle is recommendable in order to ameliorate QoL.82
In NFA patients, as well as in normal population, gender and age seem 
to be determinants of QoL.43 NFA patients are older than patients with 
other pituitary adenomas,19 and recent data indicated that female NFA 
patients have physical and emotional problems, reduced energy and 
poorer health perception in comparison to their male counterparts.66 
Moreover, NFA patients with tumour recurrence have abnormal scores 
in physical ability, energy and anxiety.66 Therefore, because 20  % of 
tumours relapse 10 years after the first intervention, long-term post-
operative monitoring is highly recommended.83 
Another important aspect negatively impacting on QoL in pituitary 
adenomas is radiotherapy. Some studies demonstrated that having 
received radiotherapy can impair mental health67 or energy levels of 
NFA patients,66 without affecting their general health perception.43,65,84
In conclusion, specific characteristics of NFA patients, such as female 
gender, hypopituitarism (especially hypogonadism and GH deficiency) or 
tumour recurrence seem to be related with impaired QoL. Radiological 
and clinical monitoring, hormone replacement and better sleep quality 
will ameliorate the perception of health status. 
Prolactinomas
Patients with prolactinomas present poor QoL as evaluated by different 
generic questionnaires.19,85–87 Gonadal dysfunction is one of the most 
important problems in these patients. In men, decreased libido, erectile 
dysfunction and poor seminal fluid quality are frequent consequences 
of prolactin hypersecretion.88,89 In women, hyperprolactinaemia causes 
amenorrhoea, galactorrhoea, vaginal dryness, dyspareunia and decreased 
libido, which can lead to infertility.88 These reproductive impairments 
have a great influence on patient’s QoL, especially in women.86 To treat 
these reproductive impairments is important because they can impact 
on patients’ QoL even after correction of hyperprolactinaemia. 
The first-line treatment for prolactinomas, dopamine agonists, are able 
to reduce tumour size, normalise prolactin levels and relieve symptoms 
in these patients,88 but impaired QoL may persist after successful 
treatment.86 Female patients with treated microprolactinoma showed 
lower scores in physical problems, vitality, emotional aspects and 
social isolation compared with control subjects.85,86 These results were 
independent of prolactin serum values, current or previous intake of 
dopamine agonists and dosage or formulation of this treatment.86 
Mental health and psychological function measures have been 
described to be impaired in prolactinoma patients. Altered personality 
profiles have been evidenced in these patients in comparison to the 
normal population. In particular, prolactinoma patients presented 
minor extraversion, lesser novelty seeking, increased shyness and 
neuroticism compared with healthy controls.87 Moreover, it has 
been shown that women treated for microprolactinomas were more 
vulnerable to anxiety and depression symptoms than control subjects.86 
Psychological support and psychiatric treatment may prevent and 
resolve these problems, since mental health is a major factor in 
perception of QoL. 
 
In summary, prolactinoma patients (particularly women) show 
emotional and psychological problems that negatively impact QoL. 
It is important to normalise sexual/reproductive function and to 
treat psychopathology symptoms, in order to achieve significant 
improvement of QoL in these patients. Globally, QoL is impaired in 
pituitary tumours.  As in healthy subjects, women tend to have worse 
QoL than men.  Specific psychological and physical limitations are 
present in secreting adenomas (i.e., acromegaly, Cushing’s syndrome 
– both of pituitary and other origins-, and prolactinomas), often not 
completely reversible even after endocrine cure.  Thus, an earlier 
diagnosis, before irreversible co-morbidities occur, should impact 
HRQoL positively.  In larger tumours with a mass effect on surrounding 
structures (i.e., causing visual impairment or hypopituitarism), QoL may 
be impaired  by these complications. n
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